A double-negative feedback loop lin28-let-7 and tumor

Abstract

Abstract:The microRNA let-7 family, functioning as a tumor suppressor, has emerged as a regulator of stem cell differentiation and tumor repression. The RNA-binding protein lin28 is a stem cell pluripotency factor, which contributes to the maintenance of stem cell characteristics and promoting cell malignant transformation. lin28 can block the maturity of let-7 by combining with the precursors of let-7 family miRNAs, which is itself able to repress lin28 by binding to the 3′-UTR of lin28 transcripts, thus forming a feedback loop. The doublenegative feedback loop comprising lin28 and let-7 is involved in several biological processes such as differentiation of stem cell, tumorigenesis, invasion and metastasis, drug resistance and relapse, which could be a potential target for cancer therapy.

Key words:Neoplasms,MicroRNAs,RNA-binding proteins,Neoplastic stem cells

PENG Jing-Tao, MO Ren, FAN Jie. A double-negative feedback loop lin28-let-7 and tumor[J]. Journal of International Oncology, 2014, 41(3): 165-168.

References

［1］ Mathieu J, RuoholaBaker H. Regulation of stem cell populations by microRNAs［J］. Adv Exp Med Biol， 2013, 786: 329-351. ［2］ Di Leva G, Croce CM. Roles of small RNAs in tumor formation［J］. Trends Mol Med， 2010, 16(6): 257-267. ［3］ Viswanathan SR, Daley GQ. Lin28: A microRNA regulator with a macro role［J］. Cell， 2010, 140(4): 445-449. ［4］ Boyerinas B, Park SM, Hau A, et al. The role of let-7 in cell differentiation and cancer［J］. Endocr Relat Cancer， 2010, 17(1): F19-36. ［5］ Roush S, Slack FJ. The let-7 family of microRNAs［J］. Trends Cell Biol， 2008, 18(10): 505-516. ［6］ Heo I, Joo C, Cho J, et al. Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA［J］. Mol Cell， 2008, 32(2): 276-284. ［7］ Piskounova E, Polytarchou C, Thornton JE, et al. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms［J］. Cell, 2011, 147(5): 1066-1079. ［8］ Rybak A, Fuchs H, Smirnova L, et al. A feedback loop comprising lin-28 and let-7 controls prelet-7 maturation during neural stemcell commitment［J］. Nat Cell Biol, 2008, 10(8): 987-993. ［9］ Yamanaka S. Pluripotency and nuclear reprogramming［J］. Philos Trans R Soc Lond B Biol Sci, 2008, 363(1500):2079-2087. ［10］ Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28［J］. Science, 2008, 320(5872): 97-100. ［11］ Li X, Zhang J, Gao L, et al. MiR-181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit［J］. Cell Death Diffe, 2012, 19(3): 378-386. ［12］ Yang X, Lin X, Zhong X, et al. Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells［J］. Cancer Res, 2010, 70(22): 9463-9472. ［13］ Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify a subpopulation of stem cell-like cells in ovarian cancer［J］. Oncogene, 2010, 29(14): 2153-2159. ［14］ Ma W, Ma J, Xu J, et al. Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironment［J］. Cell Cycle, 2013, 12(1): 88-97. ［15］ Viswanathan SR, Powers JT, Einhorn W, et al. Lin28 promotes transformation and is associated with advanced human malignancies［J］. Nat Genet， 2009, 41(7): 843-848. ［16］ Chang TC, Zeitels LR, Hwang HW, et al. Lin-28B transactivation is necessary for Mycmediated let-7 repression and proliferation［J］. Proc Natl Acad Sci USA， 2009, 106(9): 3384-3389. ［17］ Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let7 MicroRNA, and IL6 links inflammation to cell transformation［J］. Cell， 2009, 139(4): 693-706. ［18］ Saiki Y, Ishimaru S, Mimori K, et al. Comprehensive analysis of the clinical significance of inducing pluripotent stemnessrelated gene expression in colorectal cancer cells［J］. Ann Surg Oncol， 2009, 16(9): 2638-2644. ［19］ King CE, Cuatrecasas M, Castells A, et al. LIN28B promotes colon cancer progression and metastasis［J］. Cancer Res， 2011, 71(12): 4260-4268. ［20］ Hamano R, Miyata H, Yamasaki M, et al. High expression of Lin28 is associated with tumour aggressiveness and poor prognosis of patients in oesophagus cancer［J］. Br J Cancer， 2012, 106(8): 1415-1423. ［21］ DangiGarimella S, Yun J, Eves EM, et al. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7［J］. EMBO J， 2009, 28(4): 347-358. ［22］ Lv K, Liu L, Wang L, et al. Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let7a miRNA in breast cancer cells［J］. PLoS One， 2012, 7(7): e40008. ［23］ Jeong SH, Wu HG, Park WY. LIN28B confers radioresistance through the posttranscriptional control of KRAS［J］. Exp Mol Med， 2009, 41(12): 912-918. ［24］ Besancon R, ValsesiaWittmann S, Puisieux A, et al. Cancer stem cells: the emerging challenge of drug targeting［J］. Curr Med Chem， 2009, 16(4): 394-416. ［25］ Thornton JE, Gregory RI. How does Lin28 let7 control development and disease?［J］. Trends Cell Biol， 2012, 22(9): 474-482.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.